Zhangzhou Pientzehuang Pharmaceutical., Ltd (600436)

Basic

  • Market Cap

    CN¥152.22B

  • EV

    CN¥151.1B

  • Shares Out

    603.32M

  • Revenue

    CN¥9,678.11M

  • Employees

    2,720

Margins

  • Gross

    46.39%

  • EBITDA

    33.87%

  • Operating

    33.84%

  • Pre-Tax

    35.01%

  • Net

    29.18%

  • FCF

    30.15%

Returns (5Yr Avg)

  • ROA

    13.04%

  • ROE

    23.36%

  • ROCE

    25.59%

  • ROIC

    40.55%

Valuation (TTM)

  • P/E

    —

  • P/B

    —

  • EV/Sales

    —

  • EV/EBITDA

    —

  • EV/FCF

    —

  • EV/Gross Profit

    —

Valuation (NTM)

  • Price Target

    CN¥302.86

  • P/E

    —

  • EV/Sales

    —

  • EV/EBITDA

    —

  • EV/FCF

    —

Per Share

  • Rev

    CN¥16.07

  • Earnings (Dil)

    CN¥4.69

  • FCF

    CN¥4.84

  • Book Value

    CN¥21.56

Growth (CAGR)

  • Rev 3Yr

    14.48%

  • Rev 5Yr

    16.27%

  • Rev 10Yr

    21.79%

  • Dil EPS 3Yr

    21.1%

  • Dil EPS 5Yr

    21.92%

  • Dil EPS 10Yr

    19.35%

  • Rev Fwd 2Yr

    16.91%

  • EBITDA Fwd 2Yr

    18.7%

  • EPS Fwd 2Yr

    22.4%

  • EPS LT Growth Est

    20.75%

Dividends

  • Yield

    —

  • Payout

    26.65%

  • DPS

    CN¥1.25

  • DPS Growth 3Yr

    15.09%

  • DPS Growth 5Yr

    23.79%

  • DPS Growth 10Yr

    19.34%

  • DPS Growth Fwd 2Yr

    20.32%

Select a metric from the list below to chart it

Dec '13
Dec '15
Dec '17
Dec '19
Dec '21
LTM
Metric
Dec '13
Dec '14
Dec '15
Dec '16
Dec '17
Dec '18
Dec '19
Dec '20
Dec '21
Dec '22
LTM

Revenues

4,745.1

5,705.9

6,492.5

8,004.3

8,674.5

9,658.6

Other Revenues, Total

21.0

16.3

18.3

17.3

19.5

19.5

Total Revenues

4,766.2

5,722.3

6,510.8

8,021.6

8,694.0

9,678.1

Total Revenues % Chg.

28.3%

20.1%

13.8%

23.2%

8.4%

13.5%

Cost of Goods Sold, Total

2,754.4

3,198.4

3,584.3

3,968.0

4,734.9

5,188.9

Gross Profit

2,011.8

2,523.8

2,926.5

4,053.6

3,959.1

4,489.2

Selling General & Admin Expenses, Total

633.0

796.2

982.2

1,027.2

814.4

881.1

Provision for Bad Debts

-3.6

2.8

1.9

7.1

-6.8

-24.3

R&D Expenses

100.8

119.4

97.6

199.5

230.0

267.0

Other Operating Expenses

43.2

45.9

53.2

72.1

72.0

90.9

Other Operating Expenses, Total

773.4

964.3

1,134.9

1,305.9

1,109.6

1,214.6

Operating Income

1,238.4

1,559.5

1,791.6

2,747.7

2,849.5

3,274.6

Interest Expense, Total

-27.6

-31.1

-27.4

-32.9

-38.0

-38.6

Interest And Investment Income

130.0

95.3

149.3

144.5

171.6

191.2

Net Interest Expenses

102.4

64.2

121.9

111.6

133.6

152.6

Currency Exchange Gains (Loss)

5.1

4.7

-3.3

-3.3

7.2

7.2

Other Non Operating Income (Expenses)

-2.8

-2.7

-4.4

-21.6

-36.5

-41.1

EBT, Excl. Unusual Items

1,343.1

1,625.7

1,905.8

2,834.4

2,953.8

3,393.3

Impairment of Goodwill

-35.5

-6.1

—

—

—

—

Gain (Loss) On Sale Of Investments

-3.6

-0.0

6.7

4.5

-0.0

-19.3

Gain (Loss) On Sale Of Assets

9.7

4.6

40.3

27.6

10.0

-0.9

Asset Writedown

-1.8

—

—

-1.0

-0.3

-2.9

Other Unusual Items

15.6

20.4

26.1

3.6

14.3

18.1

EBT, Incl. Unusual Items

1,327.5

1,644.6

1,978.9

2,869.0

2,977.7

3,388.4

Income Tax Expense

198.8

257.7

289.5

404.2

454.8

494.3

Earnings From Continuing Operations

1,128.7

1,386.9

1,689.4

2,464.8

2,523.0

2,894.1

Minority Interest

14.2

-12.6

-17.8

-32.9

-50.6

-69.6

Net Income

1,142.9

1,374.4

1,671.5

2,431.9

2,472.3

2,824.5

Net Income to Common Incl Extra Items

1,142.9

1,374.4

1,671.5

2,431.9

2,472.3

2,824.5

Net Income to Common Excl. Extra Items

1,142.9

1,374.4

1,671.5

2,431.9

2,472.3

2,824.5

Total Shares Outstanding

603.2

603.3

603.3

603.3

603.3

603.3

Weighted Avg. Shares Outstanding

604.7

602.8

603.4

603.4

603.0

602.3

Weighted Avg. Shares Outstanding Dil

604.7

602.8

603.4

603.4

603.0

602.3

EPS

1.9

2.3

2.8

4.0

4.1

4.7

EPS Diluted

1.9

2.3

2.8

4.0

4.1

4.7

EBITDA

1,298.8

1,615.4

1,881.8

2,853.9

2,896.8

3,277.8